GE HealthCare today announced it is investing $80 million to expand contrast media production capacity in Norway. The investment will go toward increasing manufacturing capacity by 30% at its active pharmaceutical ingredients site in Lindesnes, Norway. As a result, the investment will create around 100 new jobs. GE HealthCare officials have committed to addressing the…

Thermo Fisher Scientific posted third-quarter results today that beat the consensus forecast on Wall Street. The company reported profits of $1.5 billion, or $3.79 per share, on sales of $10.7 billion for the three months ended Sept. 30, for a bottom-line loss of 21.3% on sales growth of 14.4% compared with Q3 2021. Adjusted to…

Medtech and pharma companies continue to support Ukraine relief efforts following Russia’s invasion. Previously, the World Health Organization announced that it was sending “essential medical supplies” to Ukraine — including its first shipment of 36 metric tons of supplies for trauma care and emergency surgery and other health supplies — to meet the needs of more than…

Owen Mumford this week announced that it has started building its new production facility in Witney, Oxfordshire in the U.K. Owen Mumford’s new Witney facility will stand as a production site for the company’s recently launched, next-generation auto-injector Aidaptus. The company has decades of experience creating its own drug delivery, blood sampling and rapid diagnostic products…

Moderna (NSDQ:MRNA) posted second-quarter results today that beat the overall consensus on Wall Street. The Cambridge, Mass.–based company reported profits of $2.8 billion, or $6.46 per share, on sales of $4.4 billion for the three months ended June 30 for a sales growth of 6,398.51% compared with Q2 2020. Earnings per share were $6.46, 40¢ ahead…

Moderna (Nasdaq:MRNA) posted first-quarter results today that beat the earnings consensus on Wall Street but slightly missed on revenue estimates. The company reported profits of $1.2 billion, or $2.84 per share, on sales of $1.9 billion for the three months ended March 31, for a sales growth of 24112% compared with Q1 2020. Earnings per…

JanOne recently announced that it has forged a partnership with a company to bottle and label its JAN101 drug. JanOne said it is preparing its investigational new drug application for FDA submission as a potential treatment for vascular complications caused by COVID-19. The drug is already planned for use in Phase 2b trials as a…